Press Release: Incannex engages Catalent to develop and manufacture cGMP-grade psilocybin drug products for clinical trials and potential commercial use

Incannex Healthcare Limited, a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, announced that it has engaged Catalent (Catalent) to develop and manufacture a cGMP-grade psilocybin drug product for: (1) use in Incannex’s proprietary psilocybin-assisted psychotherapy drug development programme and (2), potential wider commercial use. Commencing development and […]

Go to Source

Powered by WPeMatico